Literature DB >> 35475060

Bradycardia, Renal Failure, Atrioventricular-Nodal Blockade, Shock, and Hyperkalemia Syndrome: A Case Report.

Arshan Khan1, Abdelilah Lahmar2, Moiz Ehtesham3, Maria Riasat4, Muhammad Haseeb5,6.   

Abstract

Bradycardia, renal failure, atrioventricular (AV) blockade, shock, and hyperkalemia (BRASH) syndrome is an uncommon and relatively new entity that results from synergy between AV nodal blockade and renal failure leading to a vicious cycle of hypotension, profound bradycardia, and hyperkalemia. Classically, this syndrome is seen in a patient taking AV nodal blocking agents and underlying renal insufficiency. We are presenting a case of a 76-year-old female with a medical history of essential hypertension and non-insulin-dependent type 2 diabetes mellitus presented to the emergency room with a chief complaint of dizziness and generalized weakness. The patient was taking metoprolol tartrate 200 mg twice a day, amlodipine 10 mg once daily, clonidine 0.1 mg twice daily, enalapril 20 mg twice daily, and Metformin 750 mg twice daily. On presentation, the patient had symptomatic bradycardia resistant to atropine with heart rate in 30s and hypotension resistant to volume expansion. The laboratory results showed that the patient also had acute kidney injury and severe resistant hyperkalemia. The whole presentation raised the suspicion of BRASH syndrome. The patient was started on peripheral dopamine infusion for bradycardia and symptomatic hypotension. Nephrology was consulted, and the patient was started on urgent dialysis for resistant hyperkalemia. The patient was admitted to the cardiovascular intensive care unit, and all antihypertensive medication, including beta-blockers, were stopped. The patient clinically improved on the next day, the dopamine infusion was stopped, and the patient remained vitally stable. The patient was eventually discharged home with cardiology and nephrology follow-up. The purpose of this case report is to help with the early diagnosis of this under-recognized and new clinical condition and to discuss the pathophysiology and management.
Copyright © 2022, Khan et al.

Entities:  

Keywords:  acute kidney injury and brash syndrome; brash syndrome; diagnosis of brash syndrome; management of brash syndrome; pathophysiology of brash syndrome

Year:  2022        PMID: 35475060      PMCID: PMC9035307          DOI: 10.7759/cureus.23486

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  6 in total

1.  BRASH syndrome - fact or fiction? A first analysis of the prevalence and relevance of a newly described syndrome.

Authors:  Svenja Ravioli; Bertram K Woitok; Gregor Lindner
Journal:  Eur J Emerg Med       Date:  2021-04-01       Impact factor: 2.799

2.  BRASH Syndrome: Bradycardia, Renal Failure, AV Blockade, Shock, and Hyperkalemia.

Authors:  Joshua D Farkas; Brit Long; Alex Koyfman; Katherine Menson
Journal:  J Emerg Med       Date:  2020-06-18       Impact factor: 1.484

3.  A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation.

Authors:  Catherine M N O'Malley; Robert J Frumento; Mark A Hardy; Alan I Benvenisty; Tricia E Brentjens; John S Mercer; Elliott Bennett-Guerrero
Journal:  Anesth Analg       Date:  2005-05       Impact factor: 5.108

4.  Bradycardia, Renal Failure, Atrioventricular-nodal Blocker, Shock, and Hyperkalemia Syndrome Diagnosis and Literature Review.

Authors:  Yasar Sattar; Syeda Beenish Bareeqa; Hiba Rauf; Waqas Ullah; M Chadi Alraies
Journal:  Cureus       Date:  2020-02-13

5.  Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant.

Authors:  Syed Arsalan Akhter Zaidi; Danial Shaikh; Muhammad Saad; Timothy J Vittorio
Journal:  Case Rep Med       Date:  2019-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.